Agile Therapeutics (AGRX) Short Interest Ratio & Short Volume → The Presidential candidate you should REALLY be worried about (From Stansberry Research) (Ad) Free AGRX Stock Alerts $0.38 -0.02 (-5.03%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Agile Therapeutics Short Interest DataCurrent Short Volume361,300 sharesPrevious Short Volume222,100 sharesChange Vs. Previous Month+62.67%Dollar Volume Sold Short$196,185.90Short Interest Ratio / Days to Cover0.5Last Record DateMarch 15, 2024Outstanding Shares6,860,000 sharesFloat Size2,850,000 sharesShort Percent of Float12.68%Today's Trading Volume20,373 sharesAverage Trading Volume505,410 sharesToday's Volume Vs. Average4% Short Selling Agile Therapeutics ? Sign up to receive the latest short interest report for Agile Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatAGRX Short Interest Over TimeAGRX Days to Cover Over TimeAGRX Percentage of Float Shorted Over Time Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. Agile Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/2024361,300 shares $196,185.90 +62.7%12.7%0.5 $0.54 2/29/2024222,100 shares $176,569.50 +4.2%7.9%0.6 $0.80 2/15/2024213,100 shares $260,493.44 +12.2%7.5%0.6 $1.22 1/31/2024189,900 shares $290,547.00 +129.9%6.7%2.8 $1.53 1/15/202482,600 shares $154,462.00 +287.8%3.4%1.3 $1.87 12/31/202321,300 shares $41,535.00 +156.6%0.9%0.4 $1.95 Get the Latest News and Ratings for AGRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/15/20238,300 shares $16,766.00 +23.9%0.4%0.2 $2.02 11/30/20236,700 shares $13,869.00 -62.8%0.3%0.2 $2.07 11/15/202318,000 shares $40,140.00 +12.5%0.8%0.4 $2.23 10/31/202316,000 shares $28,960.00 +263.6%0.9%0.4 $1.81 10/15/20234,400 shares $7,832.00 -76.5%0.2%0.1 $1.78 9/30/202318,700 shares $44,880.00 +567.9%1.0%0.4 $2.40 9/15/20232,800 shares $5,852.00 -73.8%0.2%0.1 $2.09 8/31/202310,700 shares $27,820.00 -48.3%0.6%0.1 $2.60 8/15/202320,700 shares $45,126.00 -46.2%1.1%0.2 $2.18 7/31/202338,500 shares $111,650.00 -45.8%1.4%0.3 $2.90 7/15/202371,000 shares $202,350.00 -42.5%2.5%0.6 $2.85 6/30/2023123,400 shares $364,030.00 -36.7%4.4%1.1 $2.95 6/15/2023194,800 shares $633,100.00 +146.3%6.7%1.9 $3.25 5/31/202379,100 shares $299,789.00 +16.5%2.7%2.8 $3.79 5/15/202367,900 shares $322,525.00 +46.0%6.9%2.6 $4.75 4/30/202346,500 shares $299,925.00 +37.6%5.3%2.4 $6.45 4/15/202333,800 shares $235,924.00 +350.7%3.8%1.8 $6.98 3/31/20237,500 shares $1,680.00 -96.7%0.9%0.4 $0.22 3/15/2023225,700 shares $48,818.91 -39.7%0.6%0.3 $0.22 2/28/2023374,400 shares $89,818.56 -28.7%1.0%0.5 $0.24 2/15/2023524,900 shares $152,221.00 -25.0%1.3%0.7 $0.29 1/31/2023699,500 shares $188,865.00 +2.5%1.8%0.8 $0.27 1/15/2023682,600 shares $197,954.00 -0.1%1.7%0.8 $0.29 12/30/2022683,200 shares $155,086.40 -0.1%1.7%0.8 $0.23 12/15/2022684,100 shares $132,715.40 -18.7%1.7%0.8 $0.19 11/30/2022841,200 shares $176,652.00 -22.8%2.1%0.8 $0.21 11/15/20221,090,000 shares $253,207.00 -31.0%2.8%0.9 $0.23 10/31/20221,580,000 shares $440,820.00 +29.5%4.2%0.8 $0.28 10/15/20221,220,000 shares $318,786.00 -2.4%3.2%0.5 $0.26 9/30/20221,250,000 shares $371,125.00 -15.0%3.3%0.3 $0.30 9/15/20221,470,000 shares $588,000.00 -6.4%3.9%0.1 $0.40 8/31/20221,570,000 shares $631,925.00 -19.5%4.1%0.1 $0.40 8/15/20221,950,000 shares $1.05 million +42.3%5.1%0.2 $0.54 7/31/20221,370,000 shares $699,933.00 +77.4%3.6%0.1 $0.51CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (Ad)Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. AGRX Short Interest - Frequently Asked Questions What is Agile Therapeutics' current short interest? Short interest is the volume of Agile Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 15th, investors have sold 361,300 shares of AGRX short. 12.68% of Agile Therapeutics' shares are currently sold short. Learn More on Agile Therapeutics' current short interest. What is a good short interest percentage for Agile Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 12.68% of Agile Therapeutics' floating shares are currently sold short. Is Agile Therapeutics' short interest increasing or decreasing? Agile Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 361,300 shares, an increase of 62.7% from the previous total of 222,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Agile Therapeutics' float size? Agile Therapeutics currently has issued a total of 6,860,000 shares. Some of Agile Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Agile Therapeutics currently has a public float of 2,850,000 shares. How does Agile Therapeutics' short interest compare to its competitors? 12.68% of Agile Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Agile Therapeutics: 60 Degrees Pharmaceuticals, Inc. (1.31%), Virpax Pharmaceuticals, Inc. (0.91%), Onconetix, Inc. (0.31%), Notable Labs, Ltd. (0.08%), Mustang Bio, Inc. (0.91%), Sonoma Pharmaceuticals, Inc. (0.30%), Salarius Pharmaceuticals, Inc. (1.65%), Biophytis S.A. (2.62%), Altamira Therapeutics Ltd. (6.57%), CohBar, Inc. (0.59%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks. What does it mean to sell short Agile Therapeutics stock? Short selling AGRX is an investing strategy that aims to generate trading profit from Agile Therapeutics as its price is falling. AGRX shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Agile Therapeutics? A short squeeze for Agile Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of AGRX, which in turn drives the price of the stock up even further. How often is Agile Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AGRX, twice per month. The most recent reporting period available is March, 15 2024. More Short Interest Resources from MarketBeat Related Companies: 60 Degrees Pharmaceuticals Short Interest Data Virpax Pharmaceuticals Short Interest Data Onconetix Short Interest Data Notable Labs Short Interest Data Mustang Bio Short Interest Data Sonoma Pharmaceuticals Short Interest Data Salarius Pharmaceuticals Short Interest Data Biophytis Short Interest Data Altamira Therapeutics Short Interest Data CohBar Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AGRX) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaObama’s Forever Term [exposed]Porter & CompanyCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA once-in-a-century investment opportunityStansberry ResearchMost important medical advance in 100 yearsThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings